Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive Officer

Health and wellness industry veteran will lead the company to scale sustainable bioactives using plant cell technology instead of agriculture

Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, today announced the appointment of Frank Jaksch as the company's chief executive officer. Jaksch founded, was the longtime CEO and presently serves as Board Chair of health and wellness company ChromaDex, manufacturer of popular NAD product, Tru Niagen (Nasdaq: CDXC).

Ayana Bio launched in September 2021 as a Ginkgo Bioworks (NYSE: DNA) platform venture and uses proprietary plant cell technology rather than agricultural production to create plant bioactives for human nutrition, thus overcoming challenges in the current ingredient supply chain. Some of the most important and potent health bioactives come from plants and can only be produced through agriculture or foraging. Climate volatility and limited natural resources lead to shortcuts on purity, safety, and sustainability. The health and wellness consumer products industry needs new forms of production to tap into sustainable plant bioactives at scale.

"Through my decades in the natural products world, I've experienced how sourcing botanical ingredients from the wild or agriculture is not sustainable," said Jaksch. "Supply chain issues have impacted the botanicals industry for years, and more recently this year, war and climate change driven weather events have made it worse. As a result, product quality and consumer trust has suffered. Plant cell technology will revolutionize how the industry sources our most beneficial plant bioactives, and Ayana Bio can make these powerful ingredients more accessible to the world."

Ayana Bio's plant cell technology product pipeline includes bioactive compounds from ginseng, berries, cocoa, ginger and other high-value botanicals. Through its partnership with Ginkgo Bioworks, Ayana Bio can rapidly analyze its plant cell library to identify superior cell lines. From there, Ayana Bio grows and scales the cell lines using standardized cultivation methods in stainless steel tanks. The technology yields plant biomass with the identical molecular makeup of the plants found in nature—produced without the land, irrigation, fertilizers or pesticides required by agriculture. It also solves the standardization problems plaguing all agriculture-based supply chains and provides climate change resilience while protecting natural ecosystems and biodiversity.

"Synthetic biology has incredible potential to support human and environmental health, and we're proud to enable innovators like the Ayana Bio team to launch on Ginkgo's platform. Frank's understanding of where to apply plant cellular technology to fill unmet needs in nutrition and complementary medicine coupled with Ginkgo's platform for cell engineering has the power to transform the category," said Jason Kelly , CEO of Ginkgo Bioworks.

"Extraction from agriculture is the past; ingredient cultivation is the future," said Effendi Leonard, Ayana Bio's co-founder and chief technology officer. "We rely on plant-derived molecules for many things in our daily lives, and Ayana Bio's mission to democratize plant bioactives without agriculture limitation is not an easy feat. Ayana Bio is uniquely positioned to be able to leverage the most advanced life science technology, computation, and cellular cultivation all under one roof to bring Ayana Bio's mission to fruition."

Jaksch has more than 25 years in life sciences and food, beverage, and dietary supplement consumer products, building dietary supplement and food ingredient company ChromaDex from the ground up and taking the company public on Nasdaq. Jaksch sits on the board of directors for the Natural Products Association and is a recognized global expert on natural products chemistry, longevity and healthspan.

Ayana Bio launched in 2021 with $30 million in Series A funding provided by Viking Global Investors and Cascade Investment. Ayana Bio was launched in collaboration with Ginkgo Bioworks, the premier horizontal platform for cell programming, and with Ferment, the company creation studio that helps ideate and launch new companies that use cell programming to support human and environmental health and well-being.

About Ayana Bio

Ayana Bio makes sustainable bioactives for health and wellness products using plant cell cultivation rather than agriculture. Ayana Bio collaborates with global industry leaders in consumer packaged goods brands, supplements, specialized nutrition, over the counter, and traditional medicines to create standardized bioactives that give consumers confidence in quality and reliability—while preserving the planet. There's no better way to produce what comes from plants than using plant cells. For more information, visit www.ayanabio.com .

About Ginkgo Bioworks

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit www.ginkgobioworks.com .

About Ferment

Ferment is a company creation studio for the next wave of synthetic biology product companies. Ferment companies are powered by Ginkgo Bioworks, the world's most advanced platform for cell programming. Learn more at www.Ferment.co .

Media Contacts

Eva Palmer

ayanabio@missionnorth.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/ayana-bio-announces-appointment-of-frank-jaksch-as-chief-executive-officer-301611182.html

SOURCE Ayana Bio

News Provided by PR Newswire via QuoteMedia

Ginkgo Bioworks Holdings Inc.DNA NYSE:DNA Life Science Investing

DNA

QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems.

This decision will allow QIAGEN to refocus resources and efforts on developing and commercializing other innovative solutions within its portfolio, in particular the QIAstat-Dx system for syndromic testing, the QIAcuity portfolio of digital PCR systems and the QIAGEN Digital Insights (QDI) bioinformatics business. These are complemented by QIAGEN building on proven leadership positions in Sample technologies and the QuantiFERON-TB franchise.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several other enhancements in its GeneGlobe Design and Analysis Hub, a comprehensive research platform that integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs, and pathways. The new advancements aim to support customers with a wide range of assay customization options, from simple to complex and validated multiplex assays, while further improving the user experience.

Genetic research is moving fast, and new target genes are rapidly evolving that are not covered by standard or pre-designed assays. To keep pace and close the need gap, the new digital PCR Custom Assay Design Tool has been developed as an interface on the GeneGlobe platform. It enables customers to design and order assays for use on QIAGEN's digital PCR platform QIAcuity outside of QIAGEN's comprehensive catalog of over 200 wet-lab validated assays for copy number variations profiling in translational cancer research. Copy number variations (CNVs) are a type of genetic variation where specific segments of the DNA are copied more or fewer times than normal in the genome, potentially affecting susceptibility to diseases and response to treatment.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.

The clinical poster presentations highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B (CHB) in both HBeAg-positive and HBeAg-negative subjects.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemistry, XLEAP-SBS ™ into all reagents for its NextSeq ™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments.

"We are excited to deliver for our NextSeq 1000/2000 customers improved sequencing with faster run times, better quality, and higher output—all at lower cost per kit," said Jason Johnson , head of Global Product Management at Illumina. "XLEAP-SBS chemistry on NextSeq 1000/2000 will enable labs to perform bigger NGS projects without raising the budget, and facilitate greater adoption of multiomic approaches."

In March, the company launched its P4 flow cell (highest output of 540 Gb) with XLEAP-SBS chemistry for the NextSeq 2000, and today it announced that the XLEAP-SBS P1, P2, and P3 flow cells are all now available. XLEAP-SBS chemistry is a faster, higher quality, and more robust sequencing-by-synthesis chemistry that delivers approximately 20% faster turnaround times.

Early-access customers have shared positive feedback on improved quality, stability, and run times. Marc Monot , PhD, head of Biomics at the Institut Pasteur, said, "We were very happy with the quantity and quality of the reads. The Q is very close to Q40 and the stability is a game changer for Illumina. From the first base to the last base, [Illumina] improved the quality of the run quite a lot."

The NextSeq 1000 and NextSeq 2000 Systems are flexible and scalable mid-throughout sequencers that enable a range of applications, including single-cell, whole-exome, and RNA sequencing.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties, including the expectation for lower costs related to the storing and managing of genomic data costs. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including meeting manufacturing, quality, and performance requirements; (ii) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations once deployed, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X , Facebook , LinkedIn , Instagram , TikTok , and YouTube

Contacts

Investors:
Salli Schwartz
858-291-6421
IR@illumina.com

Media:
Samantha Beal
PR@illumina.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/illumina-launches-latest-chemistry-across-most-popular-mid-throughput-sequencers-enabling-higher-quality-and-greater-speed-for-customers-at-lower-cost-302162971.html

SOURCE Illumina, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares

"When-issued" trading expected to begin on or about June 12, 2024
Record date for distribution of GRAIL shares will be June 13, 2024
Distribution date for GRAIL shares anticipated to be June 24, 2024

Illumina, Inc. (NASDAQ: ILMN) today announced that its Board of Directors has approved the spin-off of GRAIL. GRAIL is anticipated to spin off from Illumina on June 24, 2024 and has applied to list on Nasdaq as "GRAL."

"Today's announcement marks a milestone for Illumina and signals an important step forward for the company, since the divestiture of GRAIL is one of our 2024 priorities," said Jacob Thaysen , CEO of Illumina. "As we prepare to lead the next era of genomics innovation, we believe GRAIL will play an important role in advancing the industry and improving human health. We will maintain a minority share of 14.5% in GRAIL and remain excited about GRAIL's breakthroughs in the fight against cancer. We also look forward to exploring opportunities where we can support GRAIL's work with industry-leading technologies and solutions."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Positive results from Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) Study

TrivarX Limited (‘the Company’) (ASX: TRI) is pleased to announce positive top-line results from the Company’s recently completed Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) study utilising its proprietary AI-backed algorithm, MEB-001. MEB-001 uses EEG and ECG signals recorded during sleep to identify current Major Depressive Episode (cMDE).

Keep reading...Show less

Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy

Tryptamine Therapeutics Limited (‘Tryp’ or the ‘Company’) (ASX: TYP), a clinical-stage biotechnology company is pleased to advise it has received highly encouraging, positive results from its recently completed Phase 2a clinical trial conducted in collaboration with the University of Michigan (‘UOM’) (refer ASX announcement: 10 July 2024). The results are both significant and clinically meaningful, and were presented by UOM researchers at the International Association for the Study of Pain (‘IASP’) 2024 World Congress in the Netherlands on 9 August 2024.

Keep reading...Show less

Successful Maiden Dosing of TRP-8803 (IV-Infused Psilocin) Completed in Global First

Tryptamine Therapeutics Limited (‘Tryp’ or the ‘Company’) (ASX: TYP), a clinical-stage biotechnology company focused on the development of an innovative and scalable intravenous-infused psilocin formulation which may be used in conjunction with psychotherapy to address significant unmet medical needs, is pleased to advise that it has successfully and safely completed the world’s first participant dosing using TRP-8803 (IV-infused psilocin) in a patient in Adelaide, South Australia.

Keep reading...Show less

Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3%
Favorable safety and tolerability results observed
100% of participants who completed the PACIFIC Study entered the OLE
End of Phase 2 Meeting scheduled for this summer

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies.

"We are thrilled to see a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEE patients. Additionally, we saw compelling seizure reduction in the PACIFIC placebo patients who transitioned to bexicaserin in the OLE. These data provide further support to bexicaserin's potential to offer a highly differentiated and best-in-class profile," stated Dr. Randall Kaye, Longboard's Chief Medical Officer.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive Officer

Latest News

Latest Press Releases

Related News

TOP STOCKS